Born from a Personal Journey.
Driven by Innovation.

MyelinZ began with a mission to transform lives through neurotechnology. Today, it’s a movement redefining brain and body performance, one breakthrough at a time.

Join The Movement

Our Mission: Transforming Brain Health for Earth and Space

We are here to revolutionise brain and body health and help people overcome cognitive, mental, and physical challenges — on Earth and beyond.

Vision:
Pioneering a New Era of Brain Health

Empowering millions to reclaim their cognitive and physical well-being.

The MyelinZ Voyage
So Far...

2024
Initial technology development
December 2024
The creation of the MyelinZ Group, launching a portfolio of three innovative products: ○ R-MMS: A medical device for MS. ○ BodyMirror: a brain health and wellbeing product, described as 'the new gym for the brain'. ○ MyelinSpace: transforming brain health in space
December 2024
Five US patents and trademarks are filed.
January 2025
MyelinZ signs three collaboration agreements with top global medical institutions to pilot BodyMirror.
Q3-2025
Q3-2025 BodyMirror Soft Launch

Meet Our Leadership Team

Globally dispersed, united by one mission—to develop neurotechnology that redefines brain health and unlocks human potential.

Co-Founder & CEO

Dr Zied Tayeb

Co-Founder & CTO

Samaher Garbaya

Meet Our Experts

World-class experts guiding our mission to revolutionise brain health and unlock human potential through groundbreaking brain-computer interfaces.

Recognitions & Global Awards

MyelinZ at the UK Parliament (House of Commons)

MyelinZ presenting at the Belgian Ambassador’s Residence in the UK

MyelinZ at Y Combinator London Event

MedTech Rising Star Of The Year 2024

MyelinZ starting a collaboration with NYU Langone

The R-MMS product clinical trial lanuch.

The MyelinSpace product exhibition at IAC 2024.

Founders touring various embassies around the world

Disclaimer: MyelinZ products, including BodyMirror, are intended for personal brain and body wellness and research use only. They are not classified as medical devices under EU Directive 93/42/EEC and are not intended for the diagnosis, treatment, or prevention of any disease. For regulated clinical use, MyelinZ is developing dedicated medical-grade technologies under the R‑MMS programme.

Born from a Personal Journey. Driven by Innovation.